HC Andersen Capital Events 15/02: Meet the top management in ExpreS2ion Biotechnologies
HC Andersen Capital is hosting a digital event where you can meet and ask questions directly to the top management. It is free for all to attend.
ExpreS2ion Biotechnologies - Presentation of year-end report 2022
On the 9th of February, ExpreS2ion Biotechnologies released its Q4 2022 and full-year 2022 results. In Q4 2022, the company's operating income fell 64% to SEK 1.59m, and the loss from the period amounted to SEK -48.5m in the quarter (SEK -14.3m in Q4 2021).
The operating income is as expected, as the focus is shifted from its legacy CRO business to developing pipeline candidates. The increase in operating loss is primarily attributable to an increase of about SEK 36m in R&D, primarily related to preclinical development and chemistry, manufacturing, and controls (CMC) of the breast cancer vaccine candidate, ES2B-C001. The progress follows what has previously been communicated throughout the year.
ExpreS2ion Biotechnologies enters 2023 with SEK 111m in cash position. Regarding the capital situation, the company states: "The Company plans to obtain additional sources of funding in 2023. This could be in the form of issuance of new shares, non-dilutive financing, entering license and research and development collaboration agreements, expense management activities, renegotiating terms for current outstanding debt instruments or a combination of such."
On the regulatory side, the company aims to achieve several milestones in 2023, including the Phase III study results for the ABNCoV2 COVID-19 vaccine and the completion of the preclinical program for our ES2B-C001 breast cancer vaccine.
We will run through the results and achievements with Bent Frandsen and CFO Keith Alexander, where you can ask questions live at the virtual event.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 12:54, 9 February 2023.
Wednesday 15th of February at 14:30 - 15:00
Sign up via. Link
Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations.
Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
HC Andersen Capital digitizes the relationship between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial market.